Aveanna Healthcare Holdings stock
AVAHNASDAQAveanna Healthcare Holdings Inc., HealthcareISIN US05356F1057
63Score 63 out of 100, Neutral
Price and trend
81 / 100
Price history
+46% in one yearThe chart shows daily closes over 6 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Above the 200-day line: the price is 39% above it.
Since July 2026 the 50-day line has been above the 200-day line; the trend has turned up.
Normal: the price is neither overheated nor sold off (RSI 47).
The price is 9.0% below its 52-week high. Largest decline in 6 years: 95% (June 2021 to December 2022).
Chart figures for advanced users
- SMA 50$13.08
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$9.41
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)47
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDbelow the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$6.22
- The lowest closing price of the last twelve months.
- Resistance$14.38
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Aveanna Healthcare Holdings Inc. belongs to the Medical (Care Facilities) industry (United States) and, with a market value of $2.86B, is number 25 of 56 companies in its industry on MEQIRI.
- For fiscal 2026, analysts expect on average revenue of $2.69B (up 10.7%) and adjusted earnings per share of $0.82 (up 37.4%).
- MEQIRI Score 63 out of 100 (Neutral): rank 232 of 714 in Healthcare, median 53.
Show more
- Our model puts fair value at $20.81, with the price 37% below it.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- High return on capitalReturn on invested capital 18.9% in fiscal 2025, Medical (Care Facilities) median 6.1%.Profitability 70
Weaknesses
- High debtDebt 5.24 times equity (latest quarter), Medical (Care Facilities) median 0.96.Stability 22
- Interest barely coveredOperating profit covers interest only 1.8 times.Stability 22
- Volatile share priceVolatility 48% a year over the last 12 months.Stability 22
Its standout strengths are momentum and valuation, while fundamentals and stability hold the score back.
Daily figure as of 12 Nov 2026
How the score is calculatedScore overview
Score since yesterday from 64 to 63.
Fundamental quality fluctuates.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansCrash risk medium
How well MEQIRI warnsIn the middle among smaller stocks.
From 2016 to 2025, 20 in 100 such stocks fell 30% or more within a year, against a group average of 23 in 100.
What drives the risk
- high price swings
- weak fundamentals
What lowers it
- stable momentum
- price near its 52-week high
Valuation
Valuation signal
Possible value trapIn our model the price counts as cheap below $14.86 and expensive above $34.68 (uncertainty high, based on the price swings of the past year).
Calculated with a cost of equity of 8.8%. At 9.8% the fair value would be $17.26, at 7.8% it would be $26.13.
Possible value trap: looks cheap, but high risk.
Valuation metrics
From the cash-flow model alone; the profit includes one-off items, so there is no industry value.
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the twelve months to 4 Jul 2026, revenue rose 19.5% on the twelve months before. Revenue has grown solidly since 2018, at about 10% per year.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 33%, operating 11%, net 9%.
Debt & balance sheet
latest quarterDebt is elevated. Keep an eye on the interest burden and refinancing.
Earnings
- Next earnings
- 18 Mar 2027in 126 days
- Last reported
- 12 Nov 2026EPS reported $0.23 (expected $0.21)above expectations
Analyst estimates
Earnings estimates have barely changed since 15 Oct 2026.
- Earnings per share
- $0.820.0%
- Revenue
- $2.69B0.0%
- Earnings per share
- $0.910.0%
- Revenue
- $2.9B0.0%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Company outlook raised
Share price after the results: +36.1%2026 guidance raised: revenue above $2.6 billion and adjusted EBITDA above $365 million.
“Based on the strength of our second quarter results, and the continued execution of our key strategic initiatives, we are increasing our full year revenue and adjusted EBITDA guidance to a revenue range greater than $2.6 billion and adjusted EBITDA greater than $365 million.”The outlook is not part of the score and not a recommendation to buy or sell.
From the earnings call on 13 Aug 2026 (fiscal Q2 2026), read by AI.
Insiders
Open-market purchases and sales by executives, board members and major holders
No open-market purchases in the last 6 months. 7 insiders sold, $272.96M in total.
Sales say less than purchases: many insiders sell on a fixed plan, for taxes or to diversify.
- Vigano Paul R, Williams Robert M Jr, J.H. Whitney Equity Partners VII, LLCSale
21 Aug 2026, Major holder
- Shares
- 2,250,000
- Price
- $11.50
- Value
- $25.88M
- Vigano Paul R, Williams Robert M Jr, J.H. Whitney Equity Partners VII, LLCSale
20 Aug 2026, Major holder
- Shares
- 12,496,077
- Price
- $11.50
- Value
- $143.7M
- Vigano Paul R, Williams Robert M JrSale
20 Aug 2026, Major holder
- Shares
- 2,003,925
- Price
- $11.50
- Value
- $23.05M
Show 10 more
- Windley Rodney DSale
20 Aug 2026, Board
- Shares
- 180,000
- Price
- $11.50
- Value
- $2.07M
- Shaner JeffSale
20 Aug 2026, Chief Executive Officer
- Shares
- 90,000
- Price
- $11.50
- Value
- $1.04M
- Reisz Edwin C.Sale
20 Aug 2026, Chief Administrative Officer
- Shares
- 50,000
- Price
- $11.50
- Value
- $575,000
- Vigano Paul R, Williams Robert M JrSale
30 Jun 2026, Major holder
- Shares
- 580,965
- Price
- $8.01
- Value
- $4.65M
- J.H. Whitney Equity Partners VII, LLC, Vigano Paul R, Williams Robert M JrSale
30 Jun 2026, Major holder
- Shares
- 2,419,035
- Price
- $8.01
- Value
- $19.38M
- Vigano Paul R, J.H. Whitney Equity Partners VII, LLC, Williams Robert M JrSale
24 Jun 2026, Major holder
- Shares
- 919,389
- Price
- $8.00
- Value
- $7.36M
- Vigano Paul R, Williams Robert M JrSale
24 Jun 2026, Major holder
- Shares
- 80,611
- Price
- $8.00
- Value
- $644,888
- Williams Robert M Jr, Vigano Paul RSale
3 Jun 2026, Major holder
- Shares
- 1,157,760
- Price
- $6.24
- Value
- $7.22M
- J.H. Whitney Equity Partners VII, LLC, Williams Robert M Jr, Vigano Paul RSale
3 Jun 2026, Major holder
- Shares
- 5,842,240
- Price
- $6.24
- Value
- $36.46M
- Cunningham Patrick A.Sale
20 May 2026, Chief Compliance Officer
- Shares
- 125,000
- Price
- $7.59
- Value
- $948,538
Partial trades from one filing are shown in one row, with the average price.
Source: Form 4 filings with the US Securities and Exchange Commission. Grants, option exercises, gifts and tax withholdings are hidden. Not a recommendation to buy.
What happened at Aveanna Healthcare Holdings
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
714 rated companies in Healthcare
- This company
- 63
- Sector median
- 53
Categories against the sector median
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Medical (Care Facilities)
The next larger and next smaller companies by market value
- Acadia HealthcareACHC $3.61B47
- Surgery PartnersSGRY $3.49B53
- National HealthCareNHC $3.3B68
- Guardian Pharmacy ServicesGRDN $3.16B77
- Ardent HealthARDT $2.56B60
- Pediatrix Medical GroupMD $2.46B70
- Addus HomeCareADUS $2.34B71
- Brookdale Senior LivingBKD $2.2B24
ETFs that hold Aveanna Healthcare Holdings
Held by 9 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| L&G Russell 2000 US Small Cap Quality UCITS ETFETLZ | 0.04% | 0.30% | €185.82M |
| Xtrackers Russell 2000 UCITS ETF 1CXRS2 | 0.04% | 0.30% | €2.17B |
| State Street SPDR Russell 2000 U.S. Small Cap UCITS ETF (Acc)ZPRR | 0.03% | 0.30% | €4.22B |
Show 5 more
| State Street SPDR MSCI USA Small Cap Value Weighted UCITS ETFZPRV | 0.02% | 0.30% | €944.34M |
| State Street SPDR MSCI World Small Cap UCITS ETF (Acc)ZPRS | 0.01% | 0.45% | €1.53B |
| iShares MSCI USA Small Cap CTB Enhanced ESG UCITS ETFSXRG | 0.01% | 0.43% | €2.48B |
| UBS MSCI USA Select Factor Mix UCITS ETF USD accUSUE | 0.00% | 0.25% | €175.89M |
| State Street SPDR MSCI All Country World Investable Market UCITS ETF (Acc)SPYI | 0.00% | 0.17% | €8.6B |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 12 Nov 2026, recalculated nightly
- Price
- Closing price of 11 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 3 Jan 2026
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Neutral, published since 7 Nov 2026 (in the score history since 7 Nov 2025)
- Valuation signal Fairly valued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.